Therapeutic Asset Ratings

374 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
phe885 Plasma Cell Myeloma	Novartis Pharmaceuticals	P2	CCC (48)
Cetuximab KRAS G12C Mutant Solid Tumors	Novartis Pharmaceuticals	P1/2	CCC (48)
Enzalutamide Ovarian Clear Cell Carcinoma	Novartis Pharmaceuticals	P1/2	CCC (48)
FULVESTRANT KRAS G12C Mutant Solid Tumors	Novartis Pharmaceuticals	P1/2	CCC (48)
gsk1120212 KRAS G12C Mutant Solid Tumors	Novartis Pharmaceuticals	P1/2	CCC (48)
Letrozole KRAS G12C Mutant Solid Tumors	Novartis Pharmaceuticals	P1/2	CCC (48)
LEUPROLIDE KRAS G12C Mutant Solid Tumors	Novartis Pharmaceuticals	P1/2	CCC (48)
Opnurasib Lung Cancer	Novartis Pharmaceuticals	P1/2	CCC (48)
Opnurasib Colorectal Carcinoma	Novartis Pharmaceuticals	P1/2	CCC (48)
Opnurasib KRAS G12C Mutant Solid Tumors	Novartis Pharmaceuticals	P1/2	CCC (48)
Opnurasib Lung Neoplasm	Novartis Pharmaceuticals	P1/2	CCC (48)
Pyrotinib KRAS G12C Mutant Solid Tumors	Novartis Pharmaceuticals	P1/2	CCC (48)
Pyrotinib Neoplasms, Lung	Novartis Pharmaceuticals	P1/2	CCC (48)
rc48-adc KRAS G12C Mutant Solid Tumors	Novartis Pharmaceuticals	P1/2	CCC (48)
rc48-adc Neoplasms, Lung	Novartis Pharmaceuticals	P1/2	CCC (48)
Ribociclib KRAS G12C Mutant Solid Tumors	Novartis Pharmaceuticals	P1/2	CCC (48)
Ribociclib Non-Small Cell Lung Cancer	Novartis Pharmaceuticals	P1/2	CCC (48)
Tislelizumab KRAS G12C Mutant Solid Tumors	Novartis Pharmaceuticals	P1/2	CCC (48)
Tislelizumab Lung Neoplasm	Novartis Pharmaceuticals	P1/2	CCC (48)
Tulmimetostat Ovarian Clear Cell Carcinoma	Novartis Pharmaceuticals	P1/2	CCC (48)
Zoladex KRAS G12C Mutant Solid Tumors	Novartis Pharmaceuticals	P1/2	CCC (48)
Zoladex Non-Small Cell Lung Cancer	Novartis Pharmaceuticals	P1/2	CCC (48)
fia586 Liver Disorder	Novartis Pharmaceuticals	P1	CC (47)
Autologous T cells obtained from peripheral blood mononuclear cells by leukapheresis, transduced with a self-inactivating, nonreplicating lentiviral vector, encoding a T cell chimeric antigen receptor targeting CD19. The expressed transgene comprises a CD8? leader sequence, a murine anti-CD19 single chain variable fragment (scFv) derived from the mouse hybridoma FMC63, a CD8? hinge and transmembrane region, and a 4-1BB (CD137) and CD3? (TCR?) signaling domain and is under control of the elongation factor 1 alpha (EF1?) promoter. The construct is flanked by 5' and 3' long terminal repeats (LTRs) and also contains a ? packaging signal, a Rev response element (RRE), a central polypurine tract (cPPT) sequence and an optimized Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). The leukapheresis material is enriched for CD4/CD8 T cells by positive immunoselection, activated by CD3 and CD28 agonists and transduced with the vector. Without further cell propagation, the T cells are washed, formulated for infusion, and cryopreserved. The substance is composed of ?80% T cells and ?1% B cells, with a mixture of transgene positive (>3.4%) and negative T cells. The CD4+ and CD8+ naïve T cell subsets (CD45RA+CCR7+) present in the leukapheresis material are largely retained Chronic Progressive Multiple Sclerosis	Novartis Pharmaceuticals	P1/2	CC (47)
Cetuximab Advanced Solid Tumors Harboring the KRAS G12C Mutation	Novartis Pharmaceuticals	P1/2	CC (47)

Showing 151 to 175 of 374 assets

PreviousPage 7 of 15Next